L-5-Methyltetrahydrofolate (L-5-MTHF) is the primary form of folate in serum and the only biologically active form in humans. It is also the only folate capable of crossing the blood-brain barrier. As the bioactive form of folic acid, L-5-MTHF is crucial for nucleic acid synthesis, cell growth, tissue repair, and embryonic development (1-4). Humans are unable to synthesize folic acid and must obtain it from dietary sources. In the body, folic acid is reduced to tetrahydrofolate, the coenzyme for one-carbon transferase, through the action of dihydrofolate reductase. Tetrahydrofolate then binds to a one-carbon unit and, via a series of enzymatic reactions, is converted into the biologically active form L-5-MTHF (5). The compound can be commercially supplied to individuals with impaired folic acid metabolism. However, current commercial production primarily depends on chemical synthesis (6-9). This presents challenges such as limited supply, safety concerns, and environmental risks (10).
Before initiating any experiments, the team underwent comprehensive online safety training, which covered pipette use and cell culturing. This training was concluded with a quiz to verify understanding. The team strictly followed iGEM Safety Policies by exclusively using the relatively safe bacterium E. coli and ensuring its containment to prevent environmental release. Additionally, the biosafety committee provided offline educational sessions.
The biosafety committee, comprising two research faculty members, is responsible for overseeing all aspects of laboratory safety. The committee conducts regular inspections to ensure proper waste disposal, sanitation, and overall safety in the work areas. Additionally, it provides personalized safety training to each team member.
The primary work area was the open bench.
The team worked with the following strains of Escherichia coli: DH5α and BL21 (DE3).